Emerald Mutual Fund Advisers Trust Purchases 162,135 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Mutual Fund Advisers Trust increased its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 19.3% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 1,003,778 shares of the medical technology company's stock after buying an additional 162,135 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 0.69% of Alphatec worth $10,178,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ATEC. Comerica Bank increased its position in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Quarry LP increased its position in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Alphatec during the 4th quarter valued at about $76,000. AlphaQuest LLC purchased a new stake in shares of Alphatec during the 4th quarter valued at about $80,000. Finally, State of Wyoming bought a new position in shares of Alphatec during the 4th quarter valued at approximately $86,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Stock Performance

Shares of ATEC traded down $0.20 during mid-day trading on Tuesday, hitting $10.71. 976,179 shares of the stock were exchanged, compared to its average volume of 2,067,881. The company has a market cap of $1.57 billion, a PE ratio of -9.31 and a beta of 1.05. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The firm has a 50-day moving average of $11.87 and a two-hundred day moving average of $11.04.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The firm had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. During the same period last year, the company earned ($0.34) earnings per share. The firm's revenue was up 22.2% on a year-over-year basis. On average, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity at Alphatec

In other Alphatec news, COO Scott Lish sold 3,982 shares of the stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $12.00, for a total value of $47,784.00. Following the sale, the chief operating officer owned 744,936 shares in the company, valued at $8,939,232. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Craig E. Hunsaker sold 13,878 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $12.36, for a total value of $171,532.08. Following the completion of the sale, the executive vice president owned 1,450,018 shares in the company, valued at approximately $17,922,222.48. The trade was a 0.95% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 299,547 shares of company stock worth $3,698,956. Company insiders own 20.90% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ATEC. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price target for the company in a research note on Monday, June 16th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.